Efficacy of Dual Glucagon and GLP-1 Agonists as New Treatments for Type II Diabetes

Globally, conditions like type 2 diabetes mellitus (T2DM) are on the rise. This situation is brought on by an increase in insulin volume and a decrease in insulin manifestation. Currently available medications are designed to either improve insulin activity or promote insulin resilience. The prevalence of type 2 diabetes mellitus in the US exceeds 26 million individuals. Long-term glycaemic control in T2D patients is still difficult to achieve despite the abundance of available therapeutic choices. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide a therapeutic option that enhances glycaemic regulation and facilitates weight loss, while presenting a little risk of hypoglycemia. A novel approach to enhancing glycaemic control and addressing the complex ecology of type 2 diabetes is to reduce dependence on glucagon and glucagon-like peptide 1 (GLP- 1). Therapeutic interventions focused on glucagon-like peptide 1 (GLP-1) offer a promising initial approach to managing type 2 diabetes mellitus (T2DM), as they effectively reduce body fat percentage and have a significant impact on cardiovascular health. The scientists involved have discovered that individuals with type 2 diabetes have inadequate responses to supraphysiological infusions of glucose-dependent insulinotropic polypeptide (GIP), resulting in its initial dismissal as an inefficient hypoglycaemic agent. The simultaneous administration of GLP-1 and GIP, as opposed to their separate administration, resulted in an altered insulin and glucagon static response, as demonstrated in a more recent study. This article provides a concise overview of the latest findings on dual glucagon and GLP-1 agonists, including a description of their mechanisms of action, clinical outcomes, advantages and disadvantages, and challenges to their development.